One to two million people worldwide are infected with the human immunodeficiency virus
type 2 (HIV-2), with highest prevalences in West African countries, but also present in …

Abstract HIV-1 and HIV-2 are the causal agents of AIDS. While similar in many ways, a
significant amount of data suggests that HIV-2 is less virulent than HIV-1. In fact, HIV-2 …

How negative selection, positive selection, and population size contribute to the large
variation in nucleotide substitution rates among RNA viruses remains unclear. Here, we …

Few studies have explored the role of neutralizing antibody (NAb) responses in controlling
HIV-2 viremia and disease progression. Using a TZM-bl neutralization assay, we assessed …

A combination of advances spanning from isolation to delivery of potent HIV-specific
antibodies has begun to revolutionize understandings of antibody-mediated antiviral activity …

Objectives: To compare the population dynamics of HIV-2 and HIV-1, and to characterize
ongoing HIV-2 transmission in rural Guinea-Bissau. Design: Phylogenetic and …

The human immunodeficiency virus (HIV) epidemic is a global issue. The estimated number
of people with HIV is 39,000,000 to date. Antiviral therapy is the primary approach to treat …

Parvovirus B19 (B19V) can cause infection in humans. To date, three genotypes of B19V,
with subtypes, are known, of which genotype 1a is the most prevalent genotype in the …

A substantial proportion of people infected with HIV-2, the second causative agent of
acquired immune deficiency syndrome (AIDS), behave as long-term non-progressors …

Although some individuals with HIV-2 develop severe immunodeficiency and AIDS-related
complications, most may never progress to AIDS. Replication-competent HIV-2 isolated from …